CTI Biopharma Corp., of Seattle, said it was informed that the independent data monitoring committee recommended continuation of the GOG-0212 phase III study of Opaxio (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a second of four planned interim analyses for survival and futility. CTI remains blinded to the interim analysis results.